RXi Pharmaceuticals

Marlborough-based RXi Pharmaceuticals, which is working on a drug to reduce dermal scarring after surgery, reported financial results for the quarter ended Sept. 30.

RXi Pharmaceuticals Corp. of Marlborough said it has received a new patent on a delivery system for the treatment diseases with an inflammatory component.

RXi Pharmaceuticals Corp., a clinical-stage biotechnology company based in Marlborough, reported that its net losses held steady at $2 million in the second quarter compared to the same period a year ago.

Marlborough-based RXi Pharmaceuticals, a clinical-stage biotechnology company, has initiated a third phase 2 study of its anti-scarring drug RXI-109.

RXi Pharmaceuticals announced it will officially open its new office and laboratory in the Marlborough Technology Center on July 9.

RXi Pharmaceuticals Corp., a clinical-stage biotechnology company based in Marlborough, narrowed its net loss to $2.28 million in the first quarter, down from $14.39 million a year earlier.

Marlborough-based RXi Pharmaceuticals Corp. , announced Friday what it called successful results of initial testing of its...

RXi Pharmaceuticals Corp., a clinical-stage biotechnology company based in Marlborough, said a Chicago-based investment firm has agreed to purchase up to $20 million in stock to advance research and development activities.

When Geert Cauwenbergh needed money for a life sciences startup in 2002, he knew where to turn: venture capitalists.

Life sciences startup RXi Pharmaceuticals of Westborough, which is pushing for federal approval of a post-surgical, anti-scarring drug, reported a net loss of nearly $21 million for 2013, although its revenue quadrupled to $400,000, the company reported.